clinical trial · NCT06079476
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Amgen·phase4·completed·n = 100
Postmenopausal OsteoporosisRomosozumab
brief summary
The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.
started
Oct 30, 2023
primary completion
Oct 18, 2025
completion
Oct 18, 2025
last updated
Nov 3, 2025
official title
An Open-label, Single-arm, Multicenter Phase 4 Study to Evaluate Safety and Tolerability of Romosozumab (EVENITY® ) in Postmenopausal Women in India With Osteoporosis and a High Risk of Fracture.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol